1. China Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Hangzhou Alltest Biotech Co., Ltd. Class A

Hangzhou Alltest Biotech Co., Ltd. Class A

SSSE:688606
44.92
CNY
-0.89
(-1.94%)
1.94EPS
21.16P/E
3.26BMarket Cap
Oct 31Next Earn
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4.27
2.26
3.15
4.03
19
25.05
42.75
9.53
10.94
11.43
11.31
Basic EPS, GAAP
0.86
0.59
0.97
1.31
11.36
10.24
14.95
2.28
3.82
2.78
1.94
Free Cash Flow per Basic Share
0.26
-0.56
-0.28
1.28
9.8
10.48
13.76
-6.42
1.37
-0.16
- -
Dividend per Share
- -
- -
- -
- -
- -
1.44
2.72
6.68
2.94
2.46
1
Book Value per Share
0.47
2.4
3.59
4.9
16.26
41.03
52.22
48.27
48.99
49.78
47.44
Tangible Book Value per Share
0.47
2.11
3.32
4.64
15.78
40.68
51.06
46.88
47.66
48.06
45.75
Basic Weighted Avg Shares
18
57
58
60
60
75
79
79
79
79
78
Sales/Revenue/Turnover
76
130
184
241
1,136
1,873
3,389
755
867
905
886
Operating Margin (%)
21.07
30.89
35.23
34.89
71.62
45.99
47.19
15.61
31.85
22.89
16.92
Depreciation Expense
1
1
2
3
4
16
58
40
32
42
- -
Net Income, GAAP
15
34
56
78
679
766
1,185
181
302
220
152
Effective Tax Rate (%)
14.57
9.51
9.78
10.84
14.2
14.5
14.19
8.69
12.89
12.38
12.96
Profit Margin (%)
20.09
26.34
30.63
32.49
59.81
40.87
34.97
23.93
34.9
24.32
17.16
Working Capital
23
59
131
200
843
2,954
3,678
2,887
2,666
2,545
2,338
LT Debt
- -
- -
- -
- -
2
17
13
8
2
7
6
Total Equity
27
139
215
293
972
3,274
4,171
3,832
3,883
3,946
3,760
Return on Invested Capital (%)
- -
40.47
31.88
31.25
103.68
34.9
31.26
4.71
7.65
5.54
3.86
Return on Capital (%)
- -
42.81
30.79
30.45
109.48
35.74
31.62
4.53
7.81
5.63
3.95
Return on Common Equity (%)
- -
41.23
31.93
30.87
107.34
36.07
31.85
4.52
7.85
5.62
3.94

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
7
7
6
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
79
79
79
Market Capitalization
5,065
4,977
3,257

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,832
2,692
2,568
Cash, Cash Equivalents & STI
2,392
2,236
2,124
Accounts Receivable, Net
159
151
145
Inventories
177
185
192
Total Current Liabilities
287
218
229
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
51.78%
1.62%
Free Cash Flow
- -
-61.31%
-111.49%
Net Income, GAAP
- -
4.6%
-27.2%
Sales/Revenue/Turnover
- -
17.49%
4.47%
Total Cash Common Dividend
- -
- -
-16.14%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
200
197
222
249
867
2025
208
221
- -
272
905
2026
195
197
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.56
1.02
0.95
1.35
3.82
2025
0.77
0.91
- -
0.39
2.78
2026
0.24
0.41
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
0.85
1.49
2.94
2025
- -
- -
- -
1
2.46
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Fei Gao
Full Time Employees
992
Sector
Health technology
Industry
Medical specialties
Address
Building 3, 4, 5 Hangzhou ZH China 310018
IPO Date
Mar 25, 2021
Website
alltests.com.cn
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Hangzhou Alltest Biotech Co., Ltd. (688606.SS) engages in the research, development, production, and sale of in vitro diagnostic reagents primarily in China and internationally. The company offers a comprehensive portfolio of rapid diagnostic products, including COVID-19 antigen and antibody tests such as SARS-CoV-2 and Influenza A+B Antigen Combo Rapid Tests (nasal swab and saliva self-testing variants), 2019-nCoV IgG/IgM Rapid Tests, and SARS-CoV-2 Neutralization Antibody Rapid Tests; infectious disease tests; women's health products like pregnancy and ovulation rapid test cassettes; drug abuse and cardiac marker tests; tumor markers; veterinary diagnostics; fluorescence immunoassay tests and analyzers; urine analysis solutions; biochemistry reagents; blood glucose monitoring systems; HB hemoglobin test meters; SARS-CoV-2 RT-qPCR assays; virus specimen stabilizers; and viral DNA/RNA extraction kits, with over 900 IVD diagnostics certified under CE, ISO13485, and MDSAP standards. Founded in 2009 and headquartered in Hangzhou, China, Hangzhou Alltest Biotech serves clinical testing, on-site testing, and personal health management markets across global regions through active participation in major trade events. In recent developments, the company agreed to acquire an undisclosed stake in Hangzhou Weisibo Medical Technology Co., Ltd. in October 2023 to expand its capabilities; reported strong 2024 financials with revenue of CNY 869.79 million and net income of CNY 303.69 million; announced plans for a cash dividend distribution of 10 yuan per 10 shares in mid-2025; and showcased innovations at 2025 events including Canton Fair, MEDICA, CMEF, and WHX Cape Town, highlighting ongoing product advancements and international outreach.